Literature DB >> 2891478

Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration.

S M Somani1, A Khalique.   

Abstract

The time course of physostigmine (Phy) and metabolites in plasma, brain, and muscle, the inhibition of butyrylcholinesterase (BuChE) in plasma, and cholinesterase (ChE) activity in brain and muscle were studied in rat after iv bolus administration of 3H-Phy (100 micrograms/kg). The semilogarithmic plot of plasma Phy concentration versus time indicates a biphasic decline. These data were analyzed by nonlinear computer fitting program (PC-NONLIN) using a two-compartment open model with bolus input and first order elimination. The pharmacokinetic constants A, B, alpha, beta, AUC, K10 half-life, alpha-half-life, beta-half-life, K10, K12, and K21 were obtained. The alpha-half-life and the beta-half-life were 1.31 and 15.01 min, respectively. The apparent volume of distribution was found to be 270 ml. The clearance was 12.43 ml min-1. The half-life of Phy in brain was 11 min. The brain to plasma ratio (1.69) peaked at 15 min. Phy is metabolized to eseroline and three other metabolites, M1, M2, and M3. The distribution studies showed that the radioactivity per g of tissue was highest in kidney and liver, whereas the percentage of the administered dose in terms of radioactivity was maximum in muscle followed by liver. The maximum inhibition of BuChE (52%) correlates with the highest Phy concentration (84.6 ng/ml) in plasma at 2 min and 70% of the enzymic activity recovered by 45 min. The maximum inhibition of ChE (63%) in the brain correlates with the highest Phy concentration (128 ng/g) at 3 min, and 85% of the enzymic activity was recovered within an hour.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891478

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Physostigmine is the antidote for anticholinergic syndrome.

Authors:  Philip W Moore; J J Rasimas; J W Donovan
Journal:  J Med Toxicol       Date:  2015-03

2.  Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats.

Authors:  Marissa A Smail; Jessica L Soles; Tracy E Karwoski; Robert T Rubin; Michael E Rhodes
Journal:  Brain Res Bull       Date:  2017-11-07       Impact factor: 4.077

3.  A subchronic application period of glucocorticoids leads to rat cognitive dysfunction whereas physostigmine induces a mild neuroprotection.

Authors:  Katrin Wüppen; Dirk Oesterle; Sabina Lewicka; Jürgen Kopitz; Konstanze Plaschke
Journal:  J Neural Transm (Vienna)       Date:  2010-07-27       Impact factor: 3.575

4.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

5.  The Carbamate, Physostigmine does not Impair Axonal Transport in Rat Cortical Neurons.

Authors:  Sean X Naughton; Wayne D Beck; Zhe Wei; Guangyu Wu; Peter W Baas; Alvin V Terry
Journal:  Neurosci Insights       Date:  2021-05-24

Review 6.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.